Pedagogical Cluster- Journal of Pedagogical Developments
PCJPD: Volume 2 Issue 4, April 2024, online: ISSN 2956-896X

PEDAGOGICAL CLUSTER
JOURNAL OF PEDAGOGICAL DEVELOPMENTS

Website: https://euroasianjournals.org/index.php/pc/index

Diagnosis and treatment of liver serosis

Tuxnazarova Shavkiya Ibatovna
Associate Professor of Operational Surgery and Topographic Anatomy
Mogadishu Feruzjon Zohid Ogli,
A student at Samarkand State Medical University

Annatation
Chronic liver disease (CLD) is an epidemic that has not been taken into account. Early death is plentiful and liver disease in the country, along with heart and respiratory disease, is among the first three in unfair health care. Fifty percent of patients with CLD are diagnosed with cirrhosis for the first time after emergency medical treatment, leading to poor patient outcomes. Traditional care models are based on secondary care when need is at the society level. Screening patients for the presence of the disease based on risk factors at population level in society allows them to determine its presence early in the presence of potential reactivity. Innovation is needed in three broad ways to improve clinical assistance in this area: improving the use of diagnostics in society, integrating diagnosis into primary and secondary care, and using digital health care to improve patient care. In this article, we will describe how the Integrated Diagnostics (ID-LIVER) project for early detection of liver disease funded by U.S. research and innovation is developing solutions to approach the issue of determining liver disease at a population level in the country. Combining NHS organizations, academic partners and trade unions is to build on innovative pathways that were previously established in Nottingham.

The goal is to jointly create and implement a commercial solution that integrates multimodal diagnosis through advanced data science to stimulate growth and disrupt the currently inadequate model. This is a targeted viewing of the wide range of applications for early diagnosis and stratification of liver disease at population level within the NHS.

Keywords: liver disease, diagnosis, road, implementation, community, artificial intelligence

Liver disease is a serious burden for health around the world and has been recognized as the main cause of death and illness in the country. In 2011, for the first time, it was noted that despite the improvement in mortality rates in neighbouring Europe, the increase in deaths from liver disease continues in England (1). This is the fifth most common cause of death in the country, and since 1970, standardized mortality rates for liver disease have increased by 400% unlike improvements in mortality for other major diseases (2). In addition, liver disease in the country is the main cause of death in the 30-49 age group (3).

The prevalence of lifestyle-related liver disease has grown over the past decade with the prevalence of diseases such as non-alcoholic fatty liver disease (NAFLD), a disease spectrum where fat content in

liver cells increases and is estimated at ~20-20. 30% (4) worldwide. Timely diagnosis carries out a potential recovery of early liver fibrosis with behavioral intervention; 90% of liver diseases are related to lifestyle (5). About 50% of patients are diagnosed with liver disease only after an emergency hospitalization (6). Liver disease is in the first three places in terms of unequal medical care (7); The average mortality rate for people with chronic liver disease (CLD) varies by 9 years in those living in the lowest-income country (8). In addition, the COVID-19 pandemic has a disproportionate impact on the CLD; The risk of death (risk level 1,5) in the study of 15,000 hospitalized patients was the highest level of all chronic diseases (9).

While good at detecting advanced diseases, there is currently not one diagnostic test available or enough to reliably detect and layer early liver disease. Traditionally, a blood test set known as "liver function tests" (LFT) is performed to determine the presence of liver disease. These include enzymes and molecules present when the liver is damaged. These tests are often requested, but often do not detect liver disease; Up to 20% of LFTs have an abnormal result, but only 1,26% of these patients were later diagnosed with chronic liver disease (10). In contrast, liver blood tests can be as normal as 90% of people with severe liver disease (11).

Other ways to assess the likelihood of a patient developing liver disease in society include non-invasive scoring systems such as the patient's blood test results and age-based FIB4 scores, which are widely used in clinical practice (12). An enlarged liver fibrosis (ELF) test can be used to predict the presence of liver fibrosis, but in the UK the presence of this test varies (13). Fibroskan is a specialized ultrasonic probe that allows for a final assessment of scar or fibrosis levels in the liver.

Early detection of liver disease in Uzbekistan

The Integrated Diagnostics (ID-LIVER) Consortium for Early Detection of Liver Disease (ID-LIVER), which is made up of NHS clinicians, academics and leaders in the fields of diagnostics and artificial intelligence (AI), is working together to develop solutions for the detection of early liver disease. We have identified three cavints that we believe will improve the detection of early liver disease. The first important gap is to improve how to diagnose liver disease at a stage when early intervention differs. The second important gap is diagnosis and transfer of primary care from hospital-based medical care to community assistance. The third important gap is to focus on diagnosis and intervention in places of necessity, based on objective information rather than historical needs. Our hypothesis is that an innovative approach combined with the expertise required to implement a clinical pathway in the NHS will help meet these three needs. The novelty of our approach includes both inter-network cooperation and broad discipline; The NHS, two major universities, and a diversity of partners covering the industry have been highlighted. The goal is to have an iterative and integrated solution that crosses the traditional boundaries of primary and secondary care. The need for a comprehensive strategy to combat the severity of liver disease was first highlighted at the national level in 2011, and the first priorities on the agenda are to strengthen early detection of liver disease (1, 2). Currently, many UK health institutions do not have official ways to diagnose and treat liver diseases. Screening of the general population for liver disease is not recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of Liver Diseases (14, 15). Local initiatives aimed at early diagnosis of liver disease among the general population have been implemented with heterogen approaches across the U.S. Below you will discuss three built-in approaches.

In the country, the Scarred Liver Project (SLP) has established a launched pathway in which a general practitioner (GP) identifies patients for screening for CLD based on risk factors. Preliminary experimental studies conducted in 2013 focus on risk factors for CLD, and the pathway also applies to etiologies of metabolic and alcohol-related disease (11, 16). Fibroskan found that patients with a high risk of CLD will undergo further examinations in second-degree medical care, while low-risk patients

will be discharged with lifestyle advice. Showed to have diagnostic efficacy and economical effectiveness in relation to standard of normal care (17, 18).

Another approach developed is the use of the "reflex" test method, which starts further tests if the result of the initial screening is abnormal. Dillon Vs. State of NYC "Intelligent LFTs" (iLFTs), which started in Dandi, Scotland, where abnormal LFT results led to a reflex cascade of subsequent blood tests. Diagnostic and management consultations based on these results are then given to the GOP (19). The ILFTs pathway was shown to allow 75% of abnormal liver blood tests to administer primary care (20). Reflex testing has also been used in the Gvent region of Wales, where the ratio of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) to LFT results is calculated automatically after abnormal ALT, which led to an increased diagnosis of patients with liver cirrhosis. community environment (21).

Two-stage differentiation pathways have been established in the regions of Uzbekistan and accepted as regular clinical assistance. An example of a two-step route is Srivastava in North London Vs. State of London. To differentiate between patients with a clinical diagnosis of NAFLD or abnormal ALT, set the "NAFLD pathway" using FIB4 scoring and ELF testing (22). Patients with a new or diagnosed NAFLD diagnosis can participate in the program, and according to preliminary FIB4 results, patients are divided into layers for those at high risk of low risk, uncertain risk or advanced liver phibramic. Later, it was reported that the rate of cirrhosis detection had tripled compared to those on the standard course of treatment.

Three separate paths have individual strengths and weaknesses. For example, starting with abnormal liver enzymes can miss a disease and focusing on risk factors will create a difficulty in resources in the short term, even if long-term savings are realized. The ability to replicate and develop these pathways will be important in the rapidly dynamic NHS landscape. Lessons from the wounded liver project

As an advanced one, the SLP is an important resource for the implementation of the future path, including project ID-LIVER.

The collaboration between primary and secondary care was vital to SLP success. As described in the Presidential Foundation's 2019 report "Acceptance and Dissemination of Innovation in the NHS," the presence of large clinical champions in primary and secondary care not only allowed co-production of the road, but was also instrumental in training stakeholders and solving problems. unavoidable problems that arise in the implementation process (23). A common sense of ownership of primary and secondary stakeholders helped to quickly resolve implementation problems and prevented conflicts between the participants.

Having a deliberate phase of experience in implementing the project in various geographical locations was important in managing potential and identifying problems early. This multi-stage process required primary care and long-term commitments, active participation and negotiation of clinical champions to secure constant funding at each stage of the process. The main obstacle to the project was based on financial budgets located within operating silos. Long-term health economic evidence was understood by commissioners, but they were limited to focusing on short-term annual budgets. Similar problems have been highlighted in many innovative reports, including the Presidential Foundation's report, that funding for the transition to clinical assistance is often cited as a key obstacle to the successful delivery of innovation (23).

Preliminary studies of the SLP were conducted in different geographical and socio-ethnic areas and showed similarities in the detection of physiological, attraction, and disease. However, it turned out in the way it was filed that only 30% of applications came from practice (Guha et al., Internal Audit - unpublished). These practices are not based on the most highly prevalent areas of disease, and this

may need special solutions to traditionally "hard-to-reach" groups (including disease characteristics and socio-ethnic factors). This study was passed on to the ID-LIVER program taking into account the need to direct areas with high liver-related diseases and mortality.

With an increase in lifestyle-related risk factors, resource adaptation with variable demand has been the main obstacle. Finding effective triage tests, especially in the context of normal liver enzyme tests, was difficult. So, it is clear the need to fine-tune the path of diagnosis; In future iterations, learning new tests or hypothetical approaches (e.g. machine learning techniques) is an attractive approach.

Active introduction of health technologies

ID-LIVER Project

An integrated diagnosis or ID-LIVER for early detection of liver disease is a new consortium focused on detecting early liver disease. We aim to use machine learning algorithms to combine patient and diagnostic data from multiple sources to develop a model for identifying patients at high risk of transition to clinically significant disease. These individuals may then be directed towards intervention to mitigate this risk with the potential to improve health outcomes and costs. The project is funded by the UK Government's Innovate UK Industrial Strategy Challenge Fund, which provides £2.5 million and provides cash allocated by industry partners worth £2 million. It represents collaborations between clinical and academic colleagues at the University of Manchester, University of Manchester NHS Foundation Trust, Nottingham University and Nottingham University Hospitals NHS Trust, as well as major industry partners GE Healthcare and Roche Diagnostics.

Northwestern U.S. occupies one of the highest in terms of liver disease prevalence, with risk factors for liver disease up to 30% of the adult population (8). In The U.S., this is true of one million people at risk of liver disease, highlighting the need for population-level diagnostic solutions. The U.S. recently changed health and social care and in 2015, 37 NHS bodies and ten districts merged to establish the U.S. Health and Social Care Cooperation (GMHSCP) as the first region with authority to oversee U.S. health and social care. In a region spanning 2.8 million residents with different socioeceal backgrounds, the goal is to jointly target health and social care to improve health outcomes.

The established clinical care pathway in the country is designed to create a pathway that facilitates primary and secondary care needs in partnership with Integrated Care System (ICS) and Primary Care Networks (PCNs). New liver assessment clinics blur the traditional paradigm of primary and secondary care. Early involvement of commission members and having clinical champions in primary and secondary care were important factors in the SLP (Lessons from Scarred Liver Project). The ID-LIVER team actively reviewed factors at every stage of the patient's journey, from identification to investigation, that not only improve performance, but also ensure equal accessibility (Department of Equality Improvement of Health Services Delivery).

Working on a public health system enables the team to approach liver disease on a scale of public health issues, compared with clinical launch teams (CCGs) that are more frequent in traditional healthcare systems. The ambition is that it provides a potential solution to the short-term and silage budget issues faced by the SLP.

The advantages of the initial pilot stage, as seen in the SLP, present a mechanism for the rapid, gradual introduction of clinics. This iterative approach makes it easy to quickly solve unique problems of individual sites and populations.

Improving health services equity

The geographical location of clinical interactions for liver assessment clinics is under constant discussion for ID-LIVER. The goal of working with sollis Clarity Health Analysis Platform is to understand the context of public health. In partnership with primary care organizations such as ICS and PCNs, we can begin to understand where risk profiles for liver disease are located geographically through the

disease's "heat maps" and then establish new team-liver assessment clinics in these areas. Clinics can be placed based on a high sick load, disproportionate liver death or liver-related outcomes. This is aimed at addressing the inaccurate redirection and improving the equality of service provided.

Open discussions with vocal, a patient and community recruitment organization, have begun in Manchester with a variety of patient groups that are risk factors for liver disease. Involving groups of patients who are "hard to reach" when designing patients is aimed at improving access to services and is an important part of improving the equity of medical care.

Identifying 'at risk' patients using digital search engines

With limited resources in the current NHS, patient identification is a pressing issue for further clinical trials. To make it easier for CLD to identify patients with risk factors, a screening of GP practices is underway using the NORTH-West company EHEALTH's FARSITE (Feasibility and Recruitment System to Improve Testing Efficiency) technology. It is a centrally controlled profiling tool that determines whether the patient has risk factors from undiscipliated notes. All patients with risk factors for liver disease can be contacted directly by GP written communication, documented in their notes, which is an important factor in the implementation of road design that meets GDPR regulations. Critically, once optimized, this technology requires very little information from busy clinical and work staff, and the speed of the invitations can be controlled to be adapted to individual assessment clinic capacity.

Following a preliminary search for central U.S. practices (which serve ~900,000 people), FARSITE identified 2005 patients with three or more risk factors who had never been tested for liver disease. Another 55,286 have one or more risk factors for liver disease. This shows just how important a potential target population is for research even in a small geographic area. So the project proves the concept if digital search engines can be integrated into the clinical pathways of medical care. Importantly, it provides a mechanism for identifying patients who have a burden of risk factors but are not differentiated for CLD, and where there is imbalance in practices.

Providing diagnostic services to those at high risk of liver disease

Optimizing resource deliveries to individuals with the greatest risk of liver-related outcomes is critical in a financially limited model. It is very important to identify those who have developed liver disease or are at high risk for early disease and disease development. We are using the AI approach to solving this so that the differentiation can be done on a wider scale than the previously defined paths. Jiva.ai, in partnership with a company that specializes in predictive analysis using artificial intelligence, we are developing an algorithmic tool to predict the risk of clinically significant liver diseases. Approximate biomarkers are prospectively approved and included in AI modeling.

Improved access and reception to clinician

There are many electronic systems for recording patients across the country that often do not interact with other systems available in health institutions. Collecting and managing a flow of several data required in patient care is often difficult. A new clinical interface, a cloud-based platform as a tool for solving this problem, is being developed in conjunction with the Roche diagnosis. Ideally, this practice will be open to all public health professionals who deal with the diagnostic pathway of the patient from nurse to consultant hepatologist, which will reduce recurrence and ensure consistency.

Available literature

1. Feruzjon, Omonova Mohigul, & Kurdasheva Ruhshona. (2024) THE ESSENCE OF VIRTUAL LABORATORY IN THE TRAINING OF NATURAL SCIENCES. *Journal of New Century Innovations*, *46*(2), 159-162. Retrieved from https://newjournal.org/index.php/new/article/view/11402

2. Son of Feruzjon Zohid, Eshmuratov Sardor Eldorovich, / Xasanov Farrux Sheraliyevich. (2023). MEASURES TO PREVENT THE TREATMENT OF LIVER DISEASES. *Teachers Three*, *46*(1), 111-112. Retrieved from https://pedagoglar.uz/index.php/01/article/view/6060
3. Zohid son, Q. F., son of Mansur, A. S., & Sheraliyevich, X. F. (2023, October). DETERMINE THE CAUSES OF GASTROINTESTINAL CANCER TREATMENT USING MEDICAL TECHNOLOGIES. IN "USA" INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE TOPICAL ISSUES OF SCIENCE (Vol. 8, No. 1).
4. Daminovich, B. S., son of Husniddin, son of I. Z., Son of Zoxid, R. A. (2024). TREATMENT OF LIVER CIRRHOSIS USING IT TECHNOLOGIES IN MEDICINE. New Stock, 1(10), 538-541.
5. Hasanov Farrux Sheraliyevich, son of Mahmood Feruzjon Zohid, son of Zaynorov Og'abek Phar'aoh (2024). INNOVATIVE SOLUTION FOR DETERMINING LIVER SEROSIS. ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 43(1), 3–10. Retrieved from https://www.newjournal.org/index.php/01/article/view/12548
6. Shamirzaev, N. Kh., S. A. Ten, and Sh. I. Tukhtanazarova. "Morphometric Characteristics of the Assessment of Physical Development of Children and Adolescents." Guidelines. Tashkent (1998).
7. Ten S. A. et al. Correlation between the parameters of anthropometric measurements in children 3-7 years old. – 2008. – №. 3. – p. 49.
8. Tukhtanazarova, Sh. I., and A. A. Mallahodzhaev. "THE ROLE OF SELENIUM IN THE CELL CYCLE AND APOPTOSIS." European Journal of Interdisciplinary Research and Development 10 (2022): 335-350.